<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Noven Pharmaceuticals Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/noven-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NOVN) Noven Pharmaceuticals Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/07/14/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy-2/9933</link>
		<comments>http://www.stockbloghub.com/2009/07/14/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy-2/9933#comments</comments>
		<pubDate>Tue, 14 Jul 2009 14:25:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Noven Pharmaceuticals Inc.]]></category>
		<category><![CDATA[NOVN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=9933</guid>
		<description><![CDATA[Noven Pharmaceuticals, Inc. (NOVN) is coming off of a great quarterly report in which revenues were up 29% and resulted in another earnings surprise. Company Description Noven develops and manufactures &#8220;transdermal&#8221; delivery systems, or in simple terms a patch that delivers medicine through the skin. The company&#8217;s products are used for attention deficit disorders and female hormone therapy. Noven also offers oral medication for other mental irregularities. Revenue Up 29% The company reported first-quarter results on May 7 that included revenue of $27.6 million, up 29% from the same quarter last year. Net income came in at $4.5 million, up from $2.6 million. Earnings per share came in at 18 cents, nickel higher than the consensus estimate and 7 cents higher than last year. This is the company&#8217;s third surprise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/14/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy-2/9933/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVN) Noven Pharmaceuticals, Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/01/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy/4961</link>
		<comments>http://www.stockbloghub.com/2009/04/01/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy/4961#comments</comments>
		<pubDate>Wed, 01 Apr 2009 18:58:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Noven Pharmaceuticals Inc.]]></category>
		<category><![CDATA[NOVN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4961</guid>
		<description><![CDATA[Noven Pharmaceuticals, Inc. (NOVN) is growing steadily and shares are responding favorably to the latest earnings release. Company Description Noven Pharmaceuticals develops and manufactures transdermal and transmucosal drug delivery products and technologies. The company&#8217;s principal commercialized products are transdermal drug delivery systems for use in hormone replacement therapy. Noven has an active research and development program with numerous products in development. Research efforts are focused primarily on four therapeutic categories: hormone replacement therapy, central nervous system conditions, cardiovascular disease and pain management. Net Income Up 25% On Mar 5 Noven announced fourth-quarter and full-year results for 2008. Full-year revenue was up 30% over 2007, to $108 million, and net income rose 25%, to $21.4 million. The increases were attributed to the joint venture entered with Novogyne Pharmaceuticals earlier in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/01/novn-noven-pharmaceuticals-inc-aggressive-growth-zacks-rank-buy/4961/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVN) Noven Pharmaceuticals -Beat Wall Street Estimates by 60% in the Third Quarter</title>
		<link>http://www.stockbloghub.com/2008/12/30/novn-noven-pharmaceuticals-beat-wall-street-estimates-by-60-in-the-third-quarter/1893</link>
		<comments>http://www.stockbloghub.com/2008/12/30/novn-noven-pharmaceuticals-beat-wall-street-estimates-by-60-in-the-third-quarter/1893#comments</comments>
		<pubDate>Tue, 30 Dec 2008 23:55:01 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Noven Pharmaceuticals Inc.]]></category>
		<category><![CDATA[NOVN]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1893</guid>
		<description><![CDATA[Noven Pharmaceuticals, Inc. (NOVN) surprised on estimates by 60% in the third quarter as revenue rose 18%. The company has surprised on estimates 3 out of the last 4 quarters by an average of 36.67%. NOVN is trading at 14.5x forward earnings. Company Description Noven Pharmaceuticals manufactures specialty drugs in three areas, transdermal drug delivery, the Novogyne joint venture with Novartis, and Noven Therapeutics. Noven&#8217;s transdermal products include Vivell-Dot, the most prescribed estrogen patch in the U.S. and Daytrana, the only patch approved for the treatment of ADHD. Noven Beat Wall Street Estimates by 60% in the Third Quarter On Nov 6, Noven announced third-quarter results that surprised on analysts&#8217; estimates by 9 cents per share. Net income was $5.2 million, or 21 cents a share. Excluding items and tax ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/30/novn-noven-pharmaceuticals-beat-wall-street-estimates-by-60-in-the-third-quarter/1893/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

